Q-omics provides the consensus-scored RPL29P7 profile across patient tissues and cancer cell-line models. RPL29P7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL29P7 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL29P7 RNA expression shows 16,967 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, KIRC, and HNSC as cancer lineages where RPL29P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P7 survival associations across molecular data types. RPL29P7 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P7 RNA expression–survival associations across cancer types. High RPL29P7 expression shows unfavorable associations in ACC and KICH, but favorable associations in BLCA, KIRP, LUSC and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL29P7 RNA expression.
This table summarizes RPL29P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P7 shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA, COAD, LUAD and LIHC. The KIRC box plot shows higher RPL29P7 RNA expression in normal versus tumor tissue (log2 FC = −0.111, t-test p < 0.001).
This table shows molecular features associated with RPL29P7 in patient tissues and cancer cell lines. In patient samples, RPL29P7 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
